Rossana Berardi

Associate Professor

Università Politecnica delle Marche

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Rossana Berardi is an Associate Professor at Università Politecnica delle Marche in Italy. Her research primarily focuses on oncology, with recent publications addressing topics such as the management of cancer pain, the effects of the COVID-19 pandemic on clinical trials, and advancements in precision medicine for breast cancer and lung cancer. She is dedicated to improving treatment outcomes through comprehensive genomic profiling and clinical trials.

Articles (16)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

Javier García-Corbacho

SPAIN

View details

Anthony M. Joshua

University Health Network

CANADA

View details

Gaia Goteri

Full Professor

ITALY

View details

Nicla La Verde

ITALY

View details

Icro Meattini

Associate Professor

University of Florence

ITALY

View details

Marianna Capecci

Associate Professor

Università Politecnica delle Marche

ITALY

View details

ida paris

Head of Breast Oncology Unit

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

ITALY

View details

GUIDO BIASCO

University of Bologna

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Rossana Berardi

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Are we doing enough to treat cancer pain? The urgent need for action in oncology practice

Germline Findings From Tumor-Only Comprehensive Genomic Profiling in the RATIONAL Study: A Missed Opportunity?

First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study

Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study

A single experience in the conduction of clinical trial during COronaVIrusDisease-2019 pandemic

Host-Related Factors in the Interplay among Inflammation, Immunity and Dormancy in Breast Cancer Recurrence and Prognosis: An Overview for Clinicians

Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine

Impact of coronavirus disease 2019 pandemic on good clinical practice trials in oncology

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives

Management of lung cancer patients during COVID-19 pandemic: dos, don’ts and don’t knows

The Impact of Lifestyle Interventions in High-Risk Early Breast Cancer Patients: A Modeling Approach from a Single Institution Experience

Contrasting Fake News in Oncology: The First Declaration of Good Communication

Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer

Re: Comments on ‘High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non–small cell lung cancer patients’

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

Seroprevalence of SARS-CoV-2–Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy

Collaborators (8)

Javier García-Corbacho

Anthony M. Joshua

Gaia Goteri

Nicla La Verde

Icro Meattini

Marianna Capecci

ida paris

GUIDO BIASCO

Make your next move.